Caroline J. Springer

13.5k total citations · 2 hit papers
127 papers, 8.9k citations indexed

About

Caroline J. Springer is a scholar working on Molecular Biology, Genetics and Biotechnology. According to data from OpenAlex, Caroline J. Springer has authored 127 papers receiving a total of 8.9k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Molecular Biology, 43 papers in Genetics and 38 papers in Biotechnology. Recurrent topics in Caroline J. Springer's work include Virus-based gene therapy research (43 papers), Cancer Research and Treatments (38 papers) and Monoclonal and Polyclonal Antibodies Research (28 papers). Caroline J. Springer is often cited by papers focused on Virus-based gene therapy research (43 papers), Cancer Research and Treatments (38 papers) and Monoclonal and Polyclonal Antibodies Research (28 papers). Caroline J. Springer collaborates with scholars based in United Kingdom, United States and Canada. Caroline J. Springer's co-authors include Richard Marais, Dan Niculescu‐Duvaz, Ion Niculescu‐Duvaz, Christopher J. Marshall, David Barford, Mathew J. Garnett, Paul Wan, Chris M. Jones, S. Mark Roe and Valerie M. Good and has published in prestigious journals such as Cell, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Caroline J. Springer

126 papers receiving 8.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

2004 2.2k citations Dan Niculescu‐Duvaz, Christopher J. Marshall et al. profile →
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

2010 1.1k citations Steven R. Whittaker, Nathalie Dhomen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Caroline J. Springer United Kingdom	44	6.6k	3.1k	1.3k	1.1k	944	127	8.9k
Alex N. Bullock United Kingdom	49	6.1k 0.9×	2.8k 0.9×	602 0.5×	872 0.8×	343 0.4×	108	8.7k
Lyubomir T. Vassilev United States	36	7.0k 1.1×	5.0k 1.6×	451 0.3×	887 0.8×	267 0.3×	70	9.3k
Gideon Bollag United States	51	10.1k 1.5×	4.6k 1.5×	691 0.5×	841 0.8×	993 1.1×	124	14.7k
Tona M. Gilmer United States	30	4.0k 0.6×	3.8k 1.2×	437 0.3×	497 0.5×	288 0.3×	60	6.8k
Carlos Garcı́a-Echeverrı́a Switzerland	48	6.7k 1.0×	2.9k 0.9×	414 0.3×	869 0.8×	206 0.2×	130	9.1k
Nicola J. Curtin United Kingdom	62	12.0k 1.8×	10.9k 3.4×	1.5k 1.2×	1.2k 1.1×	340 0.4×	197	16.7k
Shiro Akinaga Japan	43	3.7k 0.6×	1.8k 0.6×	462 0.4×	470 0.4×	267 0.3×	122	6.6k
Pascal Furet Switzerland	50	5.6k 0.8×	2.4k 0.8×	228 0.2×	2.0k 1.8×	592 0.6×	125	8.6k
Roger S. Lo United States	41	10.5k 1.6×	6.4k 2.0×	495 0.4×	408 0.4×	1.1k 1.1×	70	14.2k
Elisa de Stanchina United States	65	13.8k 2.1×	7.0k 2.2×	949 0.7×	384 0.4×	394 0.4×	226	19.4k

Countries citing papers authored by Caroline J. Springer

Since Specialization

Citations

This map shows the geographic impact of Caroline J. Springer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline J. Springer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline J. Springer more than expected).

Fields of papers citing papers by Caroline J. Springer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caroline J. Springer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline J. Springer. The network helps show where Caroline J. Springer may publish in the future.

Co-authorship network of co-authors of Caroline J. Springer

This figure shows the co-authorship network connecting the top 25 collaborators of Caroline J. Springer. A scholar is included among the top collaborators of Caroline J. Springer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caroline J. Springer. Caroline J. Springer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Jin, Jessica K.R. Boult, Andreas Heindl, et al.. (2019). Investigating the Contribution of Collagen to the Tumor Biomechanical Phenotype with Noninvasive Magnetic Resonance Elastography. Cancer Research. 79(22). 5874–5883. 43 indexed citations

Tang, Haoran, Grazia Saturno, Amaya Virós, et al.. (2017). Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface. Nature Communications. 8(1). 14909–14909. 73 indexed citations

Bridgeman, Victoria L., Elaine Y. Wan, Shane Foo, et al.. (2015). Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. Molecular Cancer Therapeutics. 15(1). 172–183. 38 indexed citations

Pedersen, Malin, Heidi V.N. Küsters‐Vandevelde, Amaya Virós, et al.. (2013). Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic NRAS in Melanocytes. Cancer Discovery. 3(4). 458–469. 51 indexed citations

Girotti, María Romina, Malin Pedersen, Berta Sanchez‐Laorden, et al.. (2012). Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma. Cancer Discovery. 3(2). 158–167. 272 indexed citations

Welti, Jonathan, Thomas Powles, Shane Foo, et al.. (2012). Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis. 15(4). 623–641. 58 indexed citations

Whittaker, Steven R., Delphine Ménard, Richard Kirk, et al.. (2010). A Novel, Selective, and Efficacious Nanomolar Pyridopyrazinone Inhibitor of V600EBRAF. Cancer Research. 70(20). 8036–8044. 15 indexed citations

Mayer, Astrid, Surinder K. Sharma, Berend Tolner, et al.. (2008). Evidence of efficacy of antibody directed enzyme prodrug therapy (ADEPT) in a Phase I trial in patients with advanced carcinoma.. Cancer Research. 68. 2 indexed citations

Dumaz, Nicolas, Robert Hayward, Jan Martin, et al.. (2006). In Melanoma, RAS Mutations Are Accompanied by Switching Signaling from BRAF to CRAF and Disrupted Cyclic AMP Signaling. Cancer Research. 66(19). 9483–9491. 241 indexed citations

10.

Springer, Caroline J.. (2004). Suicide gene therapy : methods and reviews. 11 indexed citations

11.

Springer, Caroline J.. (2004). Introduction to Vectors for Suicide Gene Therapy. Humana Press eBooks. 90. 29–46. 3 indexed citations

12.

Niculescu‐Duvaz, Dan, Ion Niculescu‐Duvaz, & Caroline J. Springer. (2004). Design of Prodrugs for Suicide Gene Therapy. Humana Press eBooks. 90. 161–202. 13 indexed citations

13.

Karasarides, Maria, Antonio Chiloeches, Robert Hayward, et al.. (2004). B-RAF is a therapeutic target in melanoma. Oncogene. 23(37). 6292–6298. 360 indexed citations

14.

Springer, Caroline J. & Ion Niculescu‐Duvaz. (2000). Prodrug-activating systems in suicide gene therapy. Journal of Clinical Investigation. 105(9). 1161–1167. 166 indexed citations

15.

McNeish, Iain A., Stephen M. Roberts, Rachel Kerr, et al.. (1998). Virus-directed enzyme prodrug therapy using retrovirally delivered E. coli nitroreductase and CB1954. British Journal of Cancer. 78. 155–156. 2 indexed citations

16.

Friedlos, Frank, et al.. (1998). Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase. Gene Therapy. 5(1). 105–112. 51 indexed citations

17.

Bridgewater, John, R.J. Knox, J. D. Pitts, Mary Collins, & Caroline J. Springer. (1997). The Bystander Effect of the Nitroreductase/CB 1954 Enzyme/Prodrug System Is Due to a Cell-Permeable Metabolite. Human Gene Therapy. 8(6). 709–717. 108 indexed citations

18.

Eccles, Sue, et al.. (1994). Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185.. PubMed. 54(19). 5171–7. 56 indexed citations

19.

Blakey, D C, B. Valcaccia, Caroline J. Springer, et al.. (1993). Antitumor effects of an antibody-carboxypeptidase g2 conjugate in combination with a benzoic acid mustard prodrug. Cell Biophysics. 22(1-3). 1–8. 16 indexed citations

20.

Calam, J, et al.. (1989). Postprandial Gastrin Concentrations Are Higher in Female Patients with Duodenal Ulcers. Digestion. 42(3). 163–166. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact